[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.167.181.242. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 662
Citations 0
Viewpoint
May 2016

Transgender Patients, Isotretinoin, and US Food and Drug Administration–Mandated Risk Evaluation and Mitigation StrategiesA Prescription for Inclusion

Author Affiliations
  • 1Department of Dermatology, Kaiser Permanente, Pleasanton, California
JAMA Dermatol. 2016;152(5):513-514. doi:10.1001/jamadermatol.2015.5547

Caitlyn Jenner has vaulted to celebrity status, Facebook has expanded its gender nomenclature, and the Pentagon has announced plans to permit transgender service members to serve openly. Although recent news about transgender persons is not uniformly rosy—transgender persons in the United States and elsewhere are still targets of violent, sometimes lethal attacks, and voters in Houston, Texas, recently repealed that city’s Equal Rights Ordinance—transgender visibility and equality have made remarkable advances. Those advances have paralleled strides made in scientific understanding of gender, including replacement of the term gender identity disorder with gender dysphoria in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition in 2013.

First Page Preview View Large
First page PDF preview
First page PDF preview
×